News

The Duke Human Vaccine Institute plays an integral role in modernizing flu vaccines.

Duke is the only institution to receive a contract in each of the three CIVICs components, including work to design and evaluate influenza vaccine approaches, manufacture and evaluate the safety and toxicity of vaccine platforms, and conduct clinical trials for influenza vaccines.

DHVI Receives Contract to Manufacture Investigational Avian Flu Vaccines

The Duke Human Vaccine Institute received funding from the National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health, to manufacture H5N1 avian flu vaccines for use in clinical trials.

NIAID recently funded $7 million to Duke under the contract called the Collaborative Influenza Vaccine Innovation Centers (CIVICs), which NIAID set up to develop new influenza vaccines that induce long-lasting immunity and protect against more variants of the virus.